Milan, Italy / Ulm, Germany | Exom Group, the Global Digital Full-Service CRO, proudly announces that its digital platform Genius ROSA has been nominated Finalist of the Scrip Awards 2019 edition for the category Best Technological Development in Clinical Trials. “This nomination confirms the value of Exom’s innovative strategy in implementing novel digital solutions into clinical trials, to better satisfy the industry expectations”, says Luigi Visani MD, President & CEO of Exom Group.

Genius ROSA is Exom’s sophisticated telemonitoring platform enabling investigators to regularly monitor patients at home and measure patient-centric clinical outcomes through mobile devices at any time during a clinical trial. “We are very proud that this solution is so well recognized by the market.” – Visani continues – “Besides collecting data at the patient’s home, a familiar environment to study participants, Genius ROSA knocks down geographical barriers by enabling the participation of those patients who live far away from the study site or who are unable to travel, such as elderly people, disabled persons, or children and infants”.

Visani emphasizes that “Genius ROSA is the ideal solution for the patient-centric study model because of the proper delivery of out-of-hospital services, and collection of home-recorded data, based on care solutions tailored to each study. Ultimately the BYOD approach, by allowing patients to use their own mobile device, provides a cost-effective, quick-start and resource-efficient tool of remote patient monitoring.”

“Exom is bringing forward the modernization of clinical trial processes through the implementation of disruptive digital solutions”, says Visani. “And this nomination shows that we are going in the right direction. We will continue to develop and offer the most innovative services and solutions to our clients.”, he concluded.

If you want to learn more about Exom and this solution please feel free to contact us.

Share This